Monotherapy for Rheumatoid Arthritis: Leveraging the Latest Evidence to Treat to Target

In this video module with accompanying downloadable slides and expert-authored ClinicalThought commentaries, learn best practices in the use of traditional, biologic, and targeted synthetic DMARD monotherapy to treat rheumatoid arthritis and discover new strategies for the multidisciplinary engagement of patients with this condition.
Roy Fleischmann, MD
Jasvinder Singh, MD, MPH


Here’s my take on the patients who are best suited to receive biologic or targeted synthetic DMARD monotherapy.

Roy Fleischmann, MD Released: June 8, 2018

What are the data supporting the use of newer agents as monotherapy for patients with RA? Here’s my take.

Jasvinder Singh, MD, MPH Released: August 2, 2018
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)

Supported by an educational grant from

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.